Review the Ondansetron source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Emerald names Ondansetron ODT (Aurobindo) with a separate 4 mg field. Boothwyn repeats a 4 mg tablet entry twice. Optimal explicitly lists 4 mg per tablet and 30 tablets. Keep ODT and conventional tablet identities separate.
Review each source row by dosage form and exact product identity. Only one entry supplies a package count. Do not treat repeated rows as additional distinct products or infer equivalent formulations.
Explore source listing4 source entries. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Ondansetron 4 mg TabletConventional tablet named; entry repeats at Boothwyn row 14; confirm whether duplicated | 4 mg tablet — source name | Count not supplied |
| Ondansetron 4 mg TabletPotential duplicate of Boothwyn row 13; not treated as another verified product | 4 mg tablet — repeated source name | Count not supplied |
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Ondansetron ODT (Aurobindo)ODT (Aurobindo) named; confirm exact product identifier, strength basis, current labeling and package | 4 mg — source strength field | Count not supplied |
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Ondansetron 4mg tablet (30 tablets) 4mg/tabletConfirm exact manufacturer, product identifier and labeling; not assumed equivalent to an ODT | 4 mg per tablet — source name | 30 tablets — source name |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
Four source rows do not establish four distinct products. The two Boothwyn rows may duplicate one entry. A named manufacturer alone does not verify a current product identifier, packaging or availability.
Reference ondansetron ODT labeling includes QT-prolongation and serotonin-syndrome warnings and contraindicates concomitant apomorphine. Confirm the exact product and labeling for each entry; a reference label does not verify all source products or make tablet and ODT formulations interchangeable. DailyMed: ondansetron ODT reference labeling
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. For a commercially manufactured product, verify its exact identity and current labeling separately. FDA: compounded drug information
Sources checked October 20, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
No equivalence is established. Confirm dosage form, manufacturer, exact product identifier, strength, package and labeling separately. The two repeated Boothwyn rows may refer to one product; only Optimal explicitly supplies a 30-tablet package.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.